In otherwise stage III NSCLC patients with a single metastatic site that is treated definitively (radiation or resection) followed by standard of care chemoradiation, would you still consider consolidation immunotherapy?   

This is a stage IV lung cancer patient and therefore in such a patient I would first evaluate molecular markers and PD-L1 as I would in any stage IV patient. The marker data will influence my decision about therapy.  In the case provided and with the limited information available I am unlikely...